ArticleDiscover oncology2025
Exploring the role of EBV ZEBRA antibody levels in papillary thyroid cancer risk and drug resistance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Posttransplant Malignant Neoplasms in Solid Organ Transplant Recipients.JAMA network open · 2026Article
- Epstein-Barr virus in thyroid disease: an integrated immunovirological perspective.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC), the most prevalent thyroid malignancy worldwide, exhibits an increasing incidence globally despite its generally favorable prognosis. Although its etiology remains partially elucidated, recent investigations have implicated specific pathogens-notably Epstein-Barr virus (EBV)-in PTC pathogenesis. To rigorously evaluate the causal relationship between EBV ZEBRA antibody levels and PTC risk, we conducted a two-sample bidirectional Mendelian randomization (MR) analysis leveraging large-scale genome-wide association study (GWAS) data. For instrumental variable selection, we identified single nucleotide polymorphisms (SNPs) strongly associated with EBV ZEBRA antibody levels (exposure traits) using a discovery GWAS of 8191 White British individuals. The outcome analysis was performed against a Finnish cohort comprising 1472 PTC cases and 314,193 controls. Our primary analysis via inverse variance-weighting (IVW) revealed a significant positive association between genetically predicted higher EBV ZEBRA antibody levels and PTC risk (p = 0.0003; odds ratio [OR] = 1.19). Notably, the intercept term analysis showed no evidence of systematic level effect bias (p = 0.46). Sensitivity analyses using the weighted median method corroborated the main findings (p = 0.01; OR = 1.21), suggesting robustness against potential confounding factors. However, inherent limitations such as residual pleiotropy, genetic linkage disequilibrium, and population-specific allele frequencies necessitate cautious interpretation. These results collectively indicate that EBV ZEBRA antibody elevation may represent a biological marker for PTC susceptibility, offering novel mechanistic insights and potential targets for early detection and preventive strategies. Further translational studies are warranted to delineate the precise molecular pathways underlying this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.